Ormco Announces Sole Distribution of OrthoPulse Gen.2 Medical Device

Article

Ormco will act as the sole U.S. Distributor for the second generation orthodontic treatment accelerating device OrthoPulse.

Ormco Announces Sole Distribution of OrthoPulse Gen.2 Medical Device

Ormco Announces Sole Distribution of OrthoPulse Gen.2 Medical Device

Orthodontic product company Ormco has announced that it will be the sole distributor of the OrthoPulse® generation 2 medical device in the United States. The OrthoPulse device is designed to help patients accelerate orthodontic treatment by using low levels of light energy to stimulate bone and move teeth, according to a press release from Ormco. The second generation OrthoPulse has a variety of improved features over the first generation such as more battery life, a water protectant design for both the charging case and mouthpiece, a more flexible mouthpiece, and an improved mobile application.

“Thanks to the innovative technology of OrthoPulse, my patients can safely and effectively accelerate their orthodontic treatment,” said Ormco customer Dr Jeff Summers in the press release. “OrthoPulse integrates easily into their daily routine, and we are also seeing that it is gentle and comfortable to help reduce pain and discomfort associated with treatment.”

Generation 2 is said to reduce treatment time for braces and clear aligners by up to 50%, and is approved by the United States Food and Drug Administration for all users. Patients can use at home every day for best results. This will be a boon for both patient and practitioner, according to Ormco President Jim McGillivary.

“Through modification of a patient’s biological response to treatment and hence shortening the orthodontic timeline, patients and doctors find this device invaluable which is why we are so excited to announce that Ormco is the sole U.S. Distributor for the latest version of the already popular OrthoPulse device,” said McGillivary in the press release. “Giving fixed and aligner patients more comfort and significantly lessening treatment time while shortening chair time and increasing predictive outcomes are all important aspects of our core business.”

Related Videos
Contemporary Cosmetic Dentistry – Part II: Arresting Marginal Caries
GNYDM23 Product Focus: CandidPro with Kristin Lange, VP of Sales at Candid
Greater New York Dental Meeting 2023 – Interview with Suzanne Cano from LunaLite Dental
Greater New York Dental Meeting 2023 – Interview with Sima Yakoby Epstein, DMD
Greater New York Dental Meeting 2023 — Interview with Shannon Carroll, RDH
Greater New York Dental Meeting 2023 — Interview with Ben Miraglia, DDS
Greater New York Dental Meeting 2023 – Interview with Daniel Weinstein from Lura Health
Greater New York Dental Meeting 2023 – Interview with Anthony P Urbanek, DDS, MS, MD
Discussing Dental Artificial Intelligence with Stephen DiBenedotto, DDS, FAGD
© 2024 MJH Life Sciences

All rights reserved.